UY27816A1 - Nueva combinacion - Google Patents

Nueva combinacion

Info

Publication number
UY27816A1
UY27816A1 UY27816A UY27816A UY27816A1 UY 27816 A1 UY27816 A1 UY 27816A1 UY 27816 A UY27816 A UY 27816A UY 27816 A UY27816 A UY 27816A UY 27816 A1 UY27816 A1 UY 27816A1
Authority
UY
Uruguay
Prior art keywords
new combination
inhibitor
pde5
cgmp
ace
Prior art date
Application number
UY27816A
Other languages
English (en)
Spanish (es)
Inventor
David Nathan Abraham Fox
Bernadette Hughes
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0211919A external-priority patent/GB0211919D0/en
Priority claimed from GB0229784A external-priority patent/GB0229784D0/en
Application filed by Pfizer filed Critical Pfizer
Publication of UY27816A1 publication Critical patent/UY27816A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
UY27816A 2002-05-23 2003-05-21 Nueva combinacion UY27816A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0211919A GB0211919D0 (en) 2002-05-23 2002-05-23 Novel combination
GB0229784A GB0229784D0 (en) 2002-12-20 2002-12-20 Novel combination

Publications (1)

Publication Number Publication Date
UY27816A1 true UY27816A1 (es) 2003-12-31

Family

ID=29585817

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27816A UY27816A1 (es) 2002-05-23 2003-05-21 Nueva combinacion

Country Status (18)

Country Link
EP (1) EP1506015A2 (fr)
JP (1) JP2005529927A (fr)
KR (1) KR20050004195A (fr)
CN (1) CN1655820A (fr)
AR (1) AR040090A1 (fr)
AU (1) AU2003223071A1 (fr)
BR (1) BR0311191A (fr)
CA (1) CA2485984A1 (fr)
IL (1) IL164975A0 (fr)
MX (1) MXPA04010951A (fr)
NO (1) NO20045517L (fr)
PA (1) PA8574201A1 (fr)
PE (1) PE20040514A1 (fr)
PL (1) PL374198A1 (fr)
RU (1) RU2004133973A (fr)
TW (1) TW200407153A (fr)
UY (1) UY27816A1 (fr)
WO (1) WO2003099194A2 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7019010B2 (en) 2001-09-27 2006-03-28 Novertis Ag Combinations
GB0318094D0 (en) * 2003-08-01 2003-09-03 Pfizer Ltd Novel combination
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1579862A1 (fr) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Utilisation des inhibiteurs de PDE III pour la réduction de la taille du coeur chez des mammifères souffrant d'insufficances cardiaques
FR2902009B1 (fr) * 2006-06-13 2012-12-07 Bioprojet Soc Civ Utilisation d'un inhibiteur de vasopeptidase pour le traitement de l'hypertension arterielle pulmonaire
CN101528042A (zh) * 2006-08-24 2009-09-09 表面线段公司 药代动力学改进的化合物
EP1920785A1 (fr) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Préparation liquide contenant un complexe du pimobendane et de la cyclodextrine
ES2924478T3 (es) 2012-03-15 2022-10-07 Boehringer Ingelheim Vetmedica Gmbh Formulación de comprimidos farmacéuticos para el sector médico veterinario, método de producción y uso de los mismos
CN105377235A (zh) 2013-07-19 2016-03-02 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316906A (en) * 1978-08-11 1982-02-23 E. R. Squibb & Sons, Inc. Mercaptoacyl derivatives of substituted prolines
GB9013750D0 (en) * 1990-06-20 1990-08-08 Pfizer Ltd Therapeutic agents
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9401090D0 (en) * 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE59803108D1 (de) * 1997-11-12 2002-03-21 Bayer Ag 2-phenyl-substituierte imidazotriazinone als phosphodiesterase inhibitoren
TWI265925B (en) * 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CN1378547A (zh) * 1999-10-11 2002-11-06 辉瑞大药厂 用作磷酸二酯酶抑制剂的5－(2－取代的－5－杂环基磺酰基吡啶－3－基)－二氢吡唑并[4,3－d]嘧啶－7－酮类化合物

Also Published As

Publication number Publication date
PE20040514A1 (es) 2004-08-24
NO20045517L (no) 2004-12-17
AU2003223071A1 (en) 2003-12-12
CN1655820A (zh) 2005-08-17
MXPA04010951A (es) 2005-06-08
KR20050004195A (ko) 2005-01-12
BR0311191A (pt) 2005-03-01
EP1506015A2 (fr) 2005-02-16
RU2004133973A (ru) 2005-09-10
PL374198A1 (en) 2005-10-03
WO2003099194A3 (fr) 2004-06-03
JP2005529927A (ja) 2005-10-06
TW200407153A (en) 2004-05-16
CA2485984A1 (fr) 2003-12-04
IL164975A0 (en) 2005-12-18
PA8574201A1 (es) 2003-12-19
AR040090A1 (es) 2005-03-16
WO2003099194A2 (fr) 2003-12-04

Similar Documents

Publication Publication Date Title
CY1105390T1 (el) Θepαπευτικη αγωγη της πνευμονικης υπερτασης
UY27816A1 (es) Nueva combinacion
ECSP056173A (es) Composicion que comprende un inhibidor de pde4 y un inhibidor de pde5
ECSP034519A (es) Inhibidores de xantina fosfodiesterasa v
DK1073658T3 (da) Pyrazolopyrimidinon-cGMP PDE5-inhibitorer til behandling af sexualforstyrrelse
DK1440709T3 (da) Kombinationer, der omfatter cGMP PDE5 inhibitorer
IS6689A (is) Forlyf af fosfónat-kirna hliðstæðum og aðferð tilað velja og búa þær til
DE60323417D1 (de) Gasturbinenverbrennungskammer
NO20001583D0 (no) Stimulering av hematopoetiske celler in vitro
DK1268480T3 (da) 8-Quinolinxanthin- og 8-isoquinolinxanthinderivater som PDE5-inhibitorer
DE60134692D1 (de) Beleuchtungsanordnung für Tastaturen und die dynamische bzw. individuelle Beleuchtung der Tasten sowie Verfahren zu ihrer Verwendung
UY27729A1 (es) Inhibidores de quinasas.
BR9710570A (pt) Inibidor de adesão de células
HN2003000285A (es) Nuevas quinazolinonas espirocondensadas y su uso como inhibidores de la fosfodiesterasa
ATE234091T1 (de) Thrombin inhibitoren
BR0314196A (pt) Inibidores de tgf-beta
GT200300231A (es) Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
MXPA05006368A (es) Inhibidores aminocianopiridina de proteina cinasa-2 activada por proteina cinasa activada por mitogeno.
PA8575501A1 (es) Nueva combinacion
DOP2003000645A (es) Nueva combinacion
PA8477601A1 (es) Inhibidores de las fkbp
ATE335824T1 (de) Isolierte luziferasen sowie deren verwendung
DE60136573D1 (de) Gewebefixativzusammensetzung
DOP2003000649A (es) Nueva combinacion
DE50308032D1 (de) Isoliertes fluoreszierendes protein aus clytia gregaria cgfp, sowie dessen verwendung

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20150520